Fig. 6.

The influence of hemichannel blockers 18α-glycyrrhetinic acid and probenecid on the ATP release response to TRPV4 agonist GSK1016790A in isosmotic Krebs solution (300 mosM). Intact lenses were exposed to isosmotic Krebs solution containing 30 nM GSK1016790A in the presence or absence of a mixture of hemichannel blockers 18α-glycyrrhetinic acid (100 μM) and probenecid (1 mM) added 20 min beforehand. ATP in the bathing solution was then measured by luciferin-luciferase assay. Values are means ± SE of results from 6–8 lenses. ***P < 0.001, significant difference from control.